Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oophorectomy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,303 result(s) found for: Oophorectomy. Displaying page 7 of 116.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2004-003617-16 Sponsor Protocol Number: D6997C00003 (9238IL/0065) Start Date*: 2004-12-24
    Sponsor Name:AstraZeneca Österreich GmbH
    Full Title: A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg ...
    Medical condition: Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002102-57 Sponsor Protocol Number: CICL670A2202 Start Date*: 2006-10-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis
    Medical condition: hereditary hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057874 Hereditary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003516-62 Sponsor Protocol Number: CYT003-QbG10 08 Start Date*: 2007-10-19
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients with Perennial Allergic Rhinoconjunctivitis.
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001582-25 Sponsor Protocol Number: D7550C00003 Start Date*: 2017-09-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 in patients with coronary artery ...
    Medical condition: Coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-011800-44 Sponsor Protocol Number: DIM20 Start Date*: 2009-10-07
    Sponsor Name:Medivation, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease
    Medical condition: Huntington disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024640-15 Sponsor Protocol Number: R17609102003 Start Date*: 2011-07-06
    Sponsor Name:Ranbaxy Laboratories Limited
    Full Title: A randomized, double-blind, placebo-controlled ‘Proof of Concept’ study of 12 week treatment with RBx 10017609 in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).
    Medical condition: Moderate to severe chronic obstructive pulmonary disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Ongoing) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013030-25 Sponsor Protocol Number: GE-067-007 Start Date*: 2010-05-12
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A Principal Open-Label Study to Compare the Brain Uptake of [18F]flutemetamol with Brain Amyloid Levels Determined Post-Mortem
    Medical condition: The subjects have a short life expectancy. GE-067-007 will determine the level of association between brain uptake of (18F)flutemetamol and brain amyloid levels. Assessments will be based on analy...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048669 Terminal state LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004386-15 Sponsor Protocol Number: MBG308 Start Date*: Information not available in EudraCT
    Sponsor Name:GE Healthcare Limited and its affiliates
    Full Title: An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma
    Medical condition: Phaeochromocytoma and Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002969-37 Sponsor Protocol Number: RA3103730 Start Date*: 2005-10-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship.
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001138-42 Sponsor Protocol Number: CLAF237A23103 Start Date*: 2006-08-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd to Placebo as Add-On Therapy in Patients with Type 2 Diabetes I...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-002588-24 Sponsor Protocol Number: CLEE011A2201 Start Date*: 2013-12-30
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized pre-surgical pharmacodynamics study to assess the biological activity of LEE011 plus letrozole versus single agent letrozole in primary breast cancer
    Medical condition: HR+, HER2- early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012094-35 Sponsor Protocol Number: D5090C00018 Start Date*: 2009-08-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment...
    Medical condition: Patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN) Intended Indication is Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029223 Neuralgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004571-41 Sponsor Protocol Number: RBMinCovid19 Start Date*: 2021-02-23
    Sponsor Name:Cyxone AB
    Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19)
    Medical condition: Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002690-19 Sponsor Protocol Number: D9150C00003 Start Date*: 2017-12-14
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, placebo-controlled, multi-centre, sequential design, phase IIa study to evaluate safety and tolerability of epicardial injections of AZD8601 during coronary bypass graf...
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004058-40 Sponsor Protocol Number: EUDARIO Start Date*: 2018-10-16
    Sponsor Name:Katholieke Universiteit Leuven
    Full Title: A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment ...
    Medical condition: Platinum-sensitive relapsed ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001863-21 Sponsor Protocol Number: FIOL Start Date*: 2018-08-14
    Sponsor Name:Vestre Viken Hospital Trust
    Full Title: First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies.
    Medical condition: Lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) LT (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004001-32 Sponsor Protocol Number: EMN27 Start Date*: 2021-01-26
    Sponsor Name: European Myeloma Network – EMN
    Full Title: A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis
    Medical condition: relapsed or refractory AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003645-41 Sponsor Protocol Number: STARDUST Start Date*: 2019-09-13
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE
    Full Title: Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non- Small-Cell Lung Cancer patients receiving concomitant steroids
    Medical condition: Non- Small-Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025122 Lung squamous cell carcinoma stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002140-10 Sponsor Protocol Number: N01125 Start Date*: 2005-08-24
    Sponsor Name:UCB Pharma S.A.
    Full Title: An open-label, multi-center, follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in s...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) GB (Completed) FI (Completed) ES (Completed) IT (Completed) SE (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002708-25 Sponsor Protocol Number: RIVAROXACS3001 (BAY59-7939/13194) Start Date*: 2008-11-27
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome The ATLAS ACS 2 ...
    Medical condition: Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) DE (Completed) PT (Completed) SK (Completed) HU (Completed) FR (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) IT (Completed) LV (Completed) CZ (Completed) BG (Completed) BE (Prematurely Ended) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:20:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA